Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2019; 16(03): 179-182
DOI: 10.1055/a-0978-3389
Aktuell diskutiert
© Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme der DGS zu Ribociclib (Kisquali®)

Further Information

Publication History

Publication Date:
11 September 2019 (online)

Also available at
    Permissions and Reprints

Stellungnahme zu allgemeinen Aspekten

Im Namen der Deutschen Gesellschaft für Senologie möchten wir im Folgenden zu dem Gutachten des IQWiG vom 11.04.2019 „Ribociclib (Mammakarzinom)“ Stellung beziehen.

Eine Heilung von Patientinnen mit metastasiertem Mammakarzinom ist nicht möglich [1]. Im Hinblick auf den palliativen Charakter der Erkrankung umfassen die therapeutischen Ziele neben einer Verlängerung des gesamten Überlebens vor allem auch eine Symptom-Kontrolle, d. h. die Verzögerung einer Progression, eine Vermeidung toxischer Therapien und den Erhalt der Lebensqualität [1] [2].

 

  • Literatur

  • 1 Cardoso F, Senkus E, Costa A. et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)dagger. Ann Oncol 2018; 29: 1634-1657
    CrossrefPubMedGoogle Scholar
  • 2 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.1, 2018 AWMF. Im Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ . Stand: 17.7.2019
    PubMedGoogle Scholar
  • 3 Rugo HS, Rumble RB, Macrae E. et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 2016; 34: 3069-3103
    CrossrefPubMedGoogle Scholar
  • 4 Thill M, Liedtke C, Muller V. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care (Basel) 2018; 13: 209-215
    CrossrefPubMedGoogle Scholar
  • 5 Arbeitsgemeinschaft Gynäkologische Onkologie e. V. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer – Version 1. 2019
    PubMedGoogle Scholar
  • 6 Cardoso F, Bischoff J, Brain E. et al. A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 2013; 39: 457-465
    CrossrefPubMedGoogle Scholar
  • 7 Hamilton E, Infante JR. Targeting CDK4/6 in patients with cancer. Cancer Treat Rev 2016; 45: 129-138
    CrossrefPubMedGoogle Scholar
  • 8 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
    CrossrefPubMedGoogle Scholar
  • 9 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
    CrossrefPubMedGoogle Scholar
  • 10 Turner NC, Ro J, Andre F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
    CrossrefPubMedGoogle Scholar
  • 11 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
    CrossrefPubMedGoogle Scholar
  • 12 Sledge GW, Toi M, Neven P. et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol 2017; 35: 2875-2884
    CrossrefPubMedGoogle Scholar
  • 13 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
    CrossrefPubMedGoogle Scholar
  • 14 Tripathy D, Im SA, Colleoni M. et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-915
    CrossrefPubMedGoogle Scholar
  • 15 Taylor CW, Green S, Dalton WS. et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol 1998; 16: 994-999
    CrossrefPubMedGoogle Scholar
  • 16 AstraZeneca. Fachinformation Zoladex® (Goserelin) 3,6 mg Implantat. Stand April 2015
    PubMedGoogle Scholar
  • 17 Hartkopf AD, Huober J, Volz B. et al. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. Breast 2018; 37: 42-51
    CrossrefPubMedGoogle Scholar
  • 18 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. IQWiG-Bericht Nr. 752 – Ribociclib (Mammakarzinom) – Nutzenbewertung gemäß § 35a SGB V. 2019. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/430/#tab/nutzenbewertung ; zuletzt aufgerufen am 03.05.2019
    PubMedGoogle Scholar
  • 19 Novartis. Dossier zur Nutzenbewertung gemäß § 35a SGB – Ribociclib (Kisquali) – Modul 1. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/430/#tab/dossier ; zuletzt aufgerufen am 03.05.2019. 2019
    PubMedGoogle Scholar
  • 20 Turner NC, Slamon DJ, Ro J. et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med 2018; 379: 1926-1936
    CrossrefPubMedGoogle Scholar
  • 21 Muller V, Nabieva N, Haberle L. et al. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. Breast 2018; 37: 154-160
    CrossrefPubMedGoogle Scholar
  • 22 Fasching PA, Esteva FJ, Pivot X. et al. Patient-reported outcomes in advanced breast cancer treated with ribociclib + fulvestrant: results from MONALEESA-3. ESMO Jahrestagung, 2018
    PubMedGoogle Scholar
  • 23 Schnipper LE, Davidson NE, Wollins DS. et al. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. J Clin Oncol 2016; 34: 2925-2934
    CrossrefPubMedGoogle Scholar
  • 24 Cherny NI, Sullivan R, Dafni U. et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573
    CrossrefPubMedGoogle Scholar
  • 25 Harbeck N, Vázquez RV, Franke F. et al. Ribociclib + tamoxifen or a non-steroidal aromatase inhibitor in premenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 patient-reported outcomes. ESMO Jahrestagung 2018
    PubMedGoogle Scholar
  • 26 Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol 2018; 10: 1758835918793326
    PubMedGoogle Scholar
  • 27 Hu W, Sung T, Jessen BA. et al. Sacaan. Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies. Clin Cancer Res 2016; 22: 2000-2008
    CrossrefPubMedGoogle Scholar
  • 28 Beck JT, Neven P, Sohn J. et al. Ribociclib treatment benefit in patients with advanced breast cancer with ≥1 dose reduction: Data from the MONALEESA-2, -3, and -7 trials. Cancer Res 2019; DOI: 10.1158/1538-7445.SABCS18-P6-18-06.
    CrossrefPubMedGoogle Scholar